Suppr超能文献

t(14;18)阴性滤泡性淋巴瘤的临床和分子分类。

The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.

机构信息

Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.

出版信息

Blood Adv. 2023 Sep 26;7(18):5258-5271. doi: 10.1182/bloodadvances.2022009456.

Abstract

Follicular lymphoma (FL) is a neoplasm derived from germinal center B cells, composed of centrocytes and centroblasts, with at least a focal follicular growth pattern. The t(14;18) translocation together with epigenetic deregulation through recurrent genetic alterations are now recognized as the hallmark of FL. Nevertheless, FL is a heterogeneous disease, clinically, morphologically, and biologically. The existence of FL lacking the t(14;18) chromosomal alteration highlights the complex pathogenesis of FL, and indicates that there are alternative pathogenetic mechanisms that can induce a neoplasm with follicular center B-cell phenotype. Based on their clinical presentation, t(14;18)-negative FLs can be divided into 3 broad groups: nodal presentation, extranodal presentation, and those affecting predominantly children and young adults. Recent studies have shed some light into the genetic alterations of t(14;18)-negative FL. Within the group of t(14;18)-negative FL with nodal presentation, cases with STAT6 mutations are increasingly recognized as a distinctive molecular subgroup, often cooccurring with CREBBP and/or TNFRSF14 mutations. FL with BCL6 rearrangement shows clinicopathological similarities to its t(14;18)-positive counterpart. In contrast, t(14;18)-negative FL in extranodal sites is characterized mainly by TNFRSF14 mutations in the absence of chromatin modifying gene mutations. FL in children have a unique molecular landscape when compared with those in adults. Pediatric-type FL (PTFL) is characterized by MAP2K1, TNFRSF14, and/or IRF8 mutations, whereas large B-cell lymphoma with IRF4 rearrangement is now recognized as a distinct entity, different from PTFL. Ultimately, a better understanding of FL biology and heterogeneity should help to understand the clinical differences and help guide patient management and treatment decisions.

摘要

滤泡性淋巴瘤(FL)是一种来源于生发中心 B 细胞的肿瘤,由中心细胞和中心母细胞组成,至少具有局灶性滤泡生长模式。t(14;18)易位以及通过反复遗传改变的表观遗传失调现在被认为是 FL 的标志。然而,FL 是一种异质性疾病,在临床上、形态上和生物学上都是如此。缺乏 t(14;18)染色体改变的 FL 的存在突出了 FL 的复杂发病机制,并表明存在可以诱导具有滤泡中心 B 细胞表型的肿瘤的替代发病机制。根据其临床表现,t(14;18)阴性 FL 可分为 3 个广泛的组:结内表现、结外表现和主要影响儿童和年轻成年人的表现。最近的研究揭示了 t(14;18)阴性 FL 的遗传改变。在 t(14;18)阴性结内表现的 FL 组中,越来越多的病例被认为是具有特征性分子亚群的 STAT6 突变,常与 CREBBP 和/或 TNFRSF14 突变同时发生。具有 BCL6 重排的 FL 具有与 t(14;18)阳性 FL 相似的临床病理特征。相比之下,t(14;18)阴性结外部位的 FL 主要特征是 TNFRSF14 突变,而无染色质修饰基因突变。与成人相比,儿童的 FL 具有独特的分子谱。儿科型 FL(PTFL)的特征是 MAP2K1、TNFRSF14 和/或 IRF8 突变,而具有 IRF4 重排的大 B 细胞淋巴瘤现在被认为是一种独特的实体,与 PTFL 不同。最终,对 FL 生物学和异质性的更好理解应有助于理解临床差异,并有助于指导患者管理和治疗决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf80/10500559/fadcefd3d48f/BLOODA_ADV-2022-009456-C-ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验